172 related articles for article (PubMed ID: 26723934)
1. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.
Murria R; Palanca S; de Juan I; Alenda C; Egoavil C; Seguí FJ; García-Casado Z; Juan MJ; Sánchez AB; Segura Á; Santaballa A; Chirivella I; Llop M; Pérez G; Barragán E; Salas D; Bolufer P
Am J Cancer Res; 2015; 5(7):2330-43. PubMed ID: 26328265
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
5. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
Tommasi S; Pinto R; Danza K; Pilato B; Palumbo O; Micale L; De Summa S
Oncotarget; 2016 Dec; 7(49):80363-80372. PubMed ID: 27385001
[TBL] [Abstract][Full Text] [Related]
6. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
7.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
8. TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours.
Maleva Kostovska I; Jakimovska M; Popovska-Jankovic K; Kubelka-Sabit K; Karagjozov M; Plaseska-Karanfilska D
Pathol Oncol Res; 2018 Oct; 24(4):937-940. PubMed ID: 29524167
[TBL] [Abstract][Full Text] [Related]
9. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
[TBL] [Abstract][Full Text] [Related]
11. Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.
Murria R; Palanca S; de Juan I; Egoavil C; Alenda C; García-Casado Z; Juan MJ; Sánchez AB; Santaballa A; Chirivella I; Segura Á; Hervás D; Llop M; Barragán E; Bolufer P
Am J Cancer Res; 2015; 5(1):375-85. PubMed ID: 25628946
[TBL] [Abstract][Full Text] [Related]
12. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
[TBL] [Abstract][Full Text] [Related]
13. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
14. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
15. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
[TBL] [Abstract][Full Text] [Related]
16. Methylation Analysis of BRCA1 and APC in Breast Cancer and It's Relationship to Clinicopathological Features.
Shakeri H; Fakhrjou A; Nikanfar A; Mohaddes-Ardebili SM
Clin Lab; 2016 Dec; 62(12):2333-2337. PubMed ID: 28164568
[TBL] [Abstract][Full Text] [Related]
17. BRCAness as a prognostic indicator in patients with early breast cancer.
Liu L; Matsunaga Y; Tsurutani J; Akashi-Tanaka S; Masuda H; Ide Y; Hashimoto R; Inuzuka M; Watanabe C; Taruno K; Sawada T; Okuyama H; Ata A; Kuwayama T; Nakayama S; Tonouchi Y; Nakamura S
Sci Rep; 2020 Dec; 10(1):21173. PubMed ID: 33273622
[TBL] [Abstract][Full Text] [Related]
18. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA in breast cancer: The association with BRCA1/2.
Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
[TBL] [Abstract][Full Text] [Related]
20. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]